{"id":1641,"date":"2023-08-17T18:48:51","date_gmt":"2023-08-17T18:48:51","guid":{"rendered":"https:\/\/healthynewsusa.com\/?p=1641"},"modified":"2023-08-17T18:48:54","modified_gmt":"2023-08-17T18:48:54","slug":"abortion-pills-legal-limbo-continues","status":"publish","type":"post","link":"https:\/\/healthynewsusa.com\/?p=1641","title":{"rendered":"Abortion Pill\u2019s Legal Limbo Continues"},"content":{"rendered":"<div>\n<div class=\"wp-block-people block--people\">\n<h3 class=\"people-title\">\n\t\tThe Host\t<\/h3>\n<div class=\"people-card-container single\">\n<div class=\"wp-block-people-card block--people-card\">\n<div class=\"author-image-container\">\n\t\t\t<img srcset=\"https:\/\/kffhealthnews.org\/wp-content\/uploads\/sites\/2\/2022\/12\/Rovner-Julie2022_sq.jpg 600w, https:\/\/kffhealthnews.org\/wp-content\/uploads\/sites\/2\/2022\/12\/Rovner-Julie2022_sq.jpg?resize=150,150 150w, https:\/\/kffhealthnews.org\/wp-content\/uploads\/sites\/2\/2022\/12\/Rovner-Julie2022_sq.jpg?resize=500,500 500w, https:\/\/kffhealthnews.org\/wp-content\/uploads\/sites\/2\/2022\/12\/Rovner-Julie2022_sq.jpg?resize=480,480 480w, https:\/\/kffhealthnews.org\/wp-content\/uploads\/sites\/2\/2022\/12\/Rovner-Julie2022_sq.jpg?resize=100,100 100w, https:\/\/kffhealthnews.org\/wp-content\/uploads\/sites\/2\/2022\/12\/Rovner-Julie2022_sq.jpg?resize=120,120 120w, https:\/\/kffhealthnews.org\/wp-content\/uploads\/sites\/2\/2022\/12\/Rovner-Julie2022_sq.jpg?resize=170,170 170w, https:\/\/kffhealthnews.org\/wp-content\/uploads\/sites\/2\/2022\/12\/Rovner-Julie2022_sq.jpg?resize=300,300 300w, https:\/\/kffhealthnews.org\/wp-content\/uploads\/sites\/2\/2022\/12\/Rovner-Julie2022_sq.jpg?resize=315,315 315w\" sizes=\"(max-width: 480px) 100vw, 150px\"\/>\n\t\t<\/div>\n<\/div><\/div>\n<\/div>\n<p>A divided three-judge federal appeals court panel has ruled that a lower court was wrong to try to reverse entirely the FDA\u2019s approval of the abortion drug mifepristone. The panel did find, however, that the agency violated regulatory rules in making the drug more easily available and that those rules should be rolled back. In practice, nothing changes immediately, because the Supreme Court has blocked the lower court\u2019s order that the drug effectively be removed from the U.S. market \u2014 for now.<\/p>\n<p>The case is pivotal for the future of reproductive health, as the pill is part of a regimen that is now the most common way American women terminate early pregnancies and is also widely used by doctors to manage miscarriages.<\/p>\n<p>Meanwhile, as President Joe Biden\u2019s Inflation Reduction Act turns one, Medicare officials are preparing to unveil which 10 drugs will be the first to face price negotiation under the new law.<\/p>\n<p>This week\u2019s panelists are Julie Rovner of KFF Health News, Shefali Luthra of The 19th, Sarah Karlin-Smith of the Pink Sheet, and Alice Miranda Ollstein of Politico.<\/p>\n<p>Among the takeaways from this week\u2019s episode:<\/p>\n<ul>\n<li>Wednesday\u2019s federal appeals court decision siding with conservative medical groups challenging mifepristone regulations has perhaps the biggest implications for the drug\u2019s distribution via telemedicine, which has been key to securing abortion access for people in areas where abortion is unavailable.<\/li>\n<li>The ongoing legal threat to mifepristone is reverberating through the drug industry, as drugmakers worry challenges to the FDA\u2019s scientific authority could cause serious problems for future drug development \u2014 especially in an industry that takes big financial risks on getting products approved.<\/li>\n<li>Texas is suing Planned Parenthood over past Medicaid payments made to the program, charging that the health organization \u201cdefrauded\u201d the state, even though the claims were made while a court had specifically allowed Planned Parenthood to remain in the program. Still, the lawsuit emphasizes just how far Texas has gone, and will go, to maintain the legal authority to not support Planned Parenthood, even in its non-abortion work.<\/li>\n<li>The federal government is expected to release the list of 10 pharmaceuticals subject to Medicare price negotiations by Sept. 1. The drugs\u2019 identities are the subject of much educated speculation, as Congress laid out in the law how drugs qualify for consideration \u2014 though even stakeholders in the drug industry are wondering which specific drugs will be up for discussion.<\/li>\n<li>A national survey of pharmacists finds drug shortages are widespread and leading to rationing at the pharmacy level. A lack of incentives to produce generic drugs is complicating supply-chain problems, leaving fewer options when there are manufacturing or other types of issues with a particular drugmaker.<\/li>\n<\/ul>\n<div class=\"wp-block block--newsletter  \" data-type=\"kaiser-health-news\/newsletter\" data-align=\"center\" style=\"\">\n<h4 class=\"newsletter__title\">\n\t\t<a href=\"https:\/\/kffhealthnews.org\/email\/\"><br \/>\n\t\t\tEmail Sign-Up\t\t<\/a><br \/>\n\t<\/h4>\n<p class=\"newsletter__description\">\n\t\tSubscribe to KFF Health News&#8217; free Morning Briefing.\t<\/p>\n<\/div>\n<p>Plus, for \u201cextra credit\u201d the panelists suggest health policy stories they read this week that they think you should read, too:<\/p>\n<p><strong>Julie Rovner:<\/strong> Time\u2019s \u201c<a href=\"https:\/\/time.com\/6303701\/a-rape-in-mississippi\/\">She Wasn\u2019t Able to Get an Abortion. Now She\u2019s a Mom. Soon She\u2019ll Start 7th Grade<\/a>,\u201d by Charlotte Alter.<\/p>\n<p><strong>Sarah Karlin-Smith:<\/strong> MIT Technology Review\u2019s \u201c<a href=\"https:\/\/www.technologyreview.com\/2023\/06\/02\/1073822\/microplastics-immune-systems\/?utm_campaign=site_visitor.unpaid.engagement&amp;utm_source=Twitter&amp;utm_medium=tr_social&amp;twclid=2-6uxjqtn46hhqycfbcxa28a671\">Microplastics Are Everywhere. What Does That Mean for Our Immune Systems\u201d<\/a>? by Jessica Hamzelou.<\/p>\n<p><strong>Shefali Luthra:<\/strong> The Atlantic\u2019s \u201c<a href=\"https:\/\/www.theatlantic.com\/ideas\/archive\/2023\/08\/housing-survey-abortion-access-gender-affirming-care-state-policies\/675017\/\">Right Price, Wrong Politics<\/a>,\u201d by Annie Lowrey.<\/p>\n<p><strong>Alice Miranda Ollstein:<\/strong> Politico\u2019s \u201c<a href=\"https:\/\/www.politico.com\/news\/2023\/08\/12\/medical-psychedelic-drugs-congress-00110851\">We\u2019re on the Cusp of Another Psychedelic Era. But This Time Washington Is Along for the Ride<\/a>,\u201d by Erin Schumaker and Katherine Ellen Foley.<\/p>\n<p>Also mentioned in this week\u2019s episode:<\/p>\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n<p><em>To hear all our podcasts,\u00a0<a href=\"https:\/\/kffhealthnews.org\/news\/tag\/podcast\/\"><u>click here<\/u><\/a>.<\/em><\/p>\n<p><em>And subscribe to KFF Health News\u2019 \u2018What the Health?\u2019 on\u00a0<a href=\"https:\/\/open.spotify.com\/show\/32EdsB662C3oyIrqLMmBXI?si=TQhRjzzLTgWtK3crfbOFtA\"><u>Spotify<\/u><\/a>,\u00a0<a href=\"https:\/\/podcasts.apple.com\/us\/podcast\/what-the-health\/id1253607372?mt=2\"><u>Apple Podcasts<\/u><\/a>,\u00a0<a href=\"https:\/\/play.pocketcasts.com\/web\/podcasts\/a379e280-3f57-0135-9028-63f4b61a9224\"><u>Pocket Casts<\/u><\/a>, or wherever you listen to podcasts.<\/em><\/p>\n<section class=\"block--category-tag-list \">\n<div class=\"category-tag-list__content-wrapper\">\n<h3 class=\"block--category-tag-list__title\">\n\t\t\t\tRelated Topics\t\t\t<\/h3>\n<p>\t\t\t\t<a class=\"category-tag-list__contact-link\" href=\"https:\/\/kffhealthnews.org\/contact-us\/\"><br \/>\n\t\t\tContact Us\t\t<\/a><br \/>\n\t\t<a class=\"category-tag-list__tip-link\" href=\"https:\/\/kffhealthnews.org\/tips\/\"><br \/>\n\t\t\tSubmit a Story Tip\t\t<\/a>\n\t<\/div>\n<\/section><\/div>\n","protected":false},"excerpt":{"rendered":"<p>The Host A divided three-judge federal appeals court panel has ruled that a lower court was wrong to try to reverse entirely the FDA\u2019s approval of the abortion drug mifepristone. The panel did find, however, that the agency violated regulatory rules in making the drug more easily available and that those rules should be rolled [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":1118,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[5],"tags":[],"class_list":["post-1641","post","type-post","status-publish","format-standard","has-post-thumbnail","category-pharmaceuticals"],"_links":{"self":[{"href":"https:\/\/healthynewsusa.com\/index.php?rest_route=\/wp\/v2\/posts\/1641","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/healthynewsusa.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/healthynewsusa.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/healthynewsusa.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/healthynewsusa.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=1641"}],"version-history":[{"count":1,"href":"https:\/\/healthynewsusa.com\/index.php?rest_route=\/wp\/v2\/posts\/1641\/revisions"}],"predecessor-version":[{"id":1642,"href":"https:\/\/healthynewsusa.com\/index.php?rest_route=\/wp\/v2\/posts\/1641\/revisions\/1642"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/healthynewsusa.com\/index.php?rest_route=\/wp\/v2\/media\/1118"}],"wp:attachment":[{"href":"https:\/\/healthynewsusa.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=1641"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/healthynewsusa.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=1641"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/healthynewsusa.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=1641"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}